The popularity of Sildenafil initially drove a boom for pharma, however recent shifts present a complicated outlook for shareholders. Off-patent alternatives are eating into earnings, and continued patent challenges https://aliciaqvpf381536.blogs100.com/41579832/sildenafil-and-pharma-a-volatile-investment